全文获取类型
收费全文 | 5954篇 |
免费 | 477篇 |
国内免费 | 8篇 |
专业分类
耳鼻咽喉 | 56篇 |
儿科学 | 217篇 |
妇产科学 | 211篇 |
基础医学 | 810篇 |
口腔科学 | 61篇 |
临床医学 | 589篇 |
内科学 | 1204篇 |
皮肤病学 | 68篇 |
神经病学 | 703篇 |
特种医学 | 99篇 |
外科学 | 531篇 |
综合类 | 63篇 |
一般理论 | 9篇 |
预防医学 | 872篇 |
眼科学 | 146篇 |
药学 | 354篇 |
中国医学 | 6篇 |
肿瘤学 | 440篇 |
出版年
2024年 | 21篇 |
2023年 | 172篇 |
2022年 | 248篇 |
2021年 | 504篇 |
2020年 | 275篇 |
2019年 | 335篇 |
2018年 | 311篇 |
2017年 | 219篇 |
2016年 | 231篇 |
2015年 | 243篇 |
2014年 | 284篇 |
2013年 | 335篇 |
2012年 | 481篇 |
2011年 | 394篇 |
2010年 | 201篇 |
2009年 | 155篇 |
2008年 | 269篇 |
2007年 | 295篇 |
2006年 | 236篇 |
2005年 | 206篇 |
2004年 | 178篇 |
2003年 | 156篇 |
2002年 | 127篇 |
2001年 | 53篇 |
2000年 | 37篇 |
1999年 | 47篇 |
1998年 | 29篇 |
1997年 | 21篇 |
1996年 | 19篇 |
1995年 | 18篇 |
1994年 | 9篇 |
1992年 | 18篇 |
1991年 | 32篇 |
1990年 | 19篇 |
1989年 | 23篇 |
1988年 | 28篇 |
1987年 | 25篇 |
1986年 | 10篇 |
1985年 | 20篇 |
1984年 | 9篇 |
1982年 | 8篇 |
1980年 | 10篇 |
1976年 | 9篇 |
1975年 | 7篇 |
1974年 | 8篇 |
1973年 | 8篇 |
1972年 | 8篇 |
1971年 | 7篇 |
1969年 | 7篇 |
1968年 | 9篇 |
排序方式: 共有6439条查询结果,搜索用时 15 毫秒
21.
Catherine A. Hogan ChunHong Huang Malaya K. Sahoo Hannah Wang Becky Jiang Mamdouh Sibai Marisa Holubar Roshni Mathew James Zehnder Benjamin A. Pinsky 《Emerging infectious diseases》2021,27(2):632
We developed an assay that detects minus-strand RNA as a surrogate for actively replicating severe acute respiratory syndrome coronavirus 2. We detected minus-strand RNA in 41 persons with coronavirus disease up to 30 days after symptom onset. This assay might inform clinical decision-making about patient infectiousness. 相似文献
22.
23.
Annie N Apple Kevin E Neuzil Hannah M Phelps Bingshan Li Harold N Lovvorn III 《Journal of pediatric surgery》2021,56(6):1135-1141
BackgroundWilms tumor (WT) affects Black children disproportionately. Genetic aberrations within WT specimens that contribute to this disparity have not been reported.MethodsThe Therapeutically Applied Research to Generate Effective Treatments (TARGET) database was queried for WT patient and genomic features. Clinical and genetic variables were compared by race.ResultsWithin the discovery set (enriched for adverse events; N = 94 White, 19 Black, 14 Other/unreported patients), Black children were more likely to present with advanced stage disease (p = 0.019). Within the validation set (primarily a random sampling of NWTS-5; N = 360 White, 92 Black, 72 Other/Unreported), Black children appeared older at diagnosis (p = 0.050), had decreased median follow-up time (p<0.0005) and were over-represented (17.4%) relative to the concurrent U.S. Census (12.8%). Among the 37 target genes sequenced, ACTB (p = 0.030) and DICER1 (p = 0.026) mutations were more common in Black patient specimens, whereas DGCR8 (p = 0.041) mutations were more common in White patient specimens. White patient specimens were more likely to contain one or multiple targeted mutations (p = 0.026).ConclusionWithin the TARGET database, Black children were over-represented and harbored WT specimens containing more frequent ACTB and DICER1 mutations. In contrast, WT from White children contained overall more mutations in targeted genes and specifically in DGCR8.Level of EvidenceIII. 相似文献
24.
25.
Ida Micaily MD Hannah Hackbart Meghan Butryn PhD Maysa M. Abu-Khalaf MD 《The breast journal》2021,27(7):603-607
Obesity is a modifiable risk factor in breast cancer patients and is predictive of disease outcomes in early-onset breast cancer survivors. The purpose of this review is to summarize the current evidence in the association between early-onset breast cancer and obesity, specifically in African-American women. Reviewing the molecular mechanisms and social determinants of disease in this population can provide a foundation for future interventions in prevention, detection, and treatment aiming at improving outcomes for young breast cancer patients. 相似文献
26.
27.
28.
Ashley Lacombe-Duncan PhD MSW Hannah Kia PhD MSW Carmen H. Logie PhD MSW Kieran P. Todd BA Yasmeen Persad Gabrielle Leblanc Kelendria Nation Ayden I. Scheim PhD Tara Lyons PhD Chavisa Horemans MES BFA Mona Loutfy MD FRCPC MPH 《Health & social care in the community》2021,29(5):e33-e46
Transgender (trans) women experience barriers to access to HIV care, which result in their lower engagement in HIV prevention, treatment and support relative to cisgender people living with HIV. Studies of trans women's barriers to HIV care have predominantly focused on perspectives of trans women, while barriers are most often described at provider, organisation and/or systems levels. Comparing perspectives of trans women and service providers may promote a shared vision for achieving health equity. Thus, this qualitative study utilised focus groups and semi-structured interviews conducted 2018–2019 to understand barriers and facilitators to HIV care from the perspectives of trans women (n = 26) and service providers (n = 10). Barriers endorsed by both groups included: (a) anticipated and enacted stigma and discrimination in the provision of direct care, (b) lack of provider knowledge of HIV care needs for trans women, (c) absence of trans-specific services/organisations and (d) cisnormativity in sexual healthcare. Facilitators included: (a) provision of trans-positive trauma-informed care, (b) autonomy and choice for trans women in selecting sexual health services and (c) models for trans-affirming systems change. Each theme had significant overlap, yet nuanced perspective, between trans women and service providers. Specific recommendations to improve HIV care access for trans women are discussed. These recommendations can be used by administrators and service providers alike to work collaboratively with trans women to reduce barriers and facilitators to HIV care and ultimately to achieve health equity for trans women. 相似文献
29.
To determine the effect of pharmacologic modulation of alterations of peripheral blood T-cell subsets caused by antigen-induced bronchoconstriction, we administered albuterol immediately after antigen-induced bronchoconstriction in a double-blind to protocol to 12 atopic asthmatic subjects. We also administered cromolyn sodium before antigen to 7 of the same subjects. Peripheral blood T-cell subset composition (CD4, CD8, la) of a highly purified T-cell preparation was determined before, 24, 48, 72, and 168 h after bronchoconstriction. We found that placebo inhalation immediately after antigen-induced bronchoconstriction did not affect subsequent peripheral blood T-cell subset changes (decrease in CD4+ and increase in Ia+ T lymphocytes). In contrast, inhaled albuterol abolished these T-cell subset changes. Although cromolyn sodium significantly decreased the severity of antigen-induced bronchoconstriction, it did not affect T-cell subset composition changes at the dosage used. We conclude that albuterol can ablate T-cell subset changes associated with antigen-induced bronchoconstriction. Cromolyn sodium ameliorates bronchoconstriction, but has no affect on T-cell subset composition changes. This implies that T-cell changes and bronchoconstriction caused by antigen inhalation are mediated through different pathways. 相似文献
30.
J P Moatti C Le Gales C Julian J L Lanoe S Ayme 《Revue d'épidémiologie et de santé publique》1990,38(4):309-321
The article presents a cost-benefit analysis of amniocentesis for detection of chromosomal anomalies based on data (1985/87) collected in the Marseille area. In this geographic area, it is possible to confront, in an exhaustive manner, pregnant women's access to amniocentesis and incidence of fetal anomalies due to chromosomal aberrations. Results show that prenatal diagnosis is highly cost-beneficial, the average cost of one "avoided" case of Down's syndrome being lower than the lifelong costs of care for such a child. However, the study emphasizes that the cost-benefit ratio is highly sensitive to the implicit value society affects to the loss of "normal" fetuses through spontaneous abortions provoked by amniocentesis and because of terminations of pregnancy following diagnosis of minor fetal anomalies. The study also shows that lowering maternal age limit for access to free-of-charge amniocentesis from the current 38 years of age to 35 would have been cost-beneficial. Such lowering of the maternal age limit is discussed and compared with other indications which might be used for systematic access to amniocentesis. 相似文献